Ind-Swift Laboratories Limited (BOM:532305)
India · Delayed Price · Currency is INR 187.25
+18.75 (11.13%)
At close: Jun 19, 2026
Ind-Swift Laboratories Revenue
In the fiscal year ending March 31, 2026, Ind-Swift Laboratories had annual revenue of 6.41B INR with 14.17% growth. Ind-Swift Laboratories had revenue of 1.70B in the quarter ending March 31, 2026, a decrease of -66.57%.
Revenue
6.41B
Revenue Growth
+14.17%
P/S Ratio
2.53
Revenue / Employee
5.15M
Employees
1,246
Market Cap
16.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.41B | 795.81M | 14.17% |
| Mar 31, 2025 | 5.62B | -11.47B | -67.13% |
| Mar 31, 2024 | 17.09B | 4.93B | 40.56% |
| Mar 31, 2023 | 12.16B | 1.63B | 15.48% |
| Mar 31, 2022 | 10.53B | 1.46B | 16.12% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 23.19B |
| Bajaj HealthCare | 6.11B |
| NGL Fine-Chem | 5.01B |
| Aarey Drugs & Pharmaceuticals | 4.72B |
| Sai Parenteral's | 3.81B |
| Anlon Healthcare | 1.72B |
| Gujarat Themis Biosyn | 1.66B |
| Influx Healthtech | 1.47B |
Ind-Swift Laboratories News
- 4 months ago - Ind-Swift Laboratories steps up export push with Rs 40 crore Jammu facility upgrade - Business Upturn